Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064203%3A_____%2F11%3A7266" target="_blank" >RIV/00064203:_____/11:7266 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11130/11:7266
Result on the web
<a href="http://www.translational-medicine.com/content/pdf/1479-5876-9-223.pdf" target="_blank" >http://www.translational-medicine.com/content/pdf/1479-5876-9-223.pdf</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials
Original language description
Background: For clinical applications, dendritic cells (DCs) need to be generated using GMP-approved reagents. In this study, we tested the characteristics of DCs generated in two clinical grade culture media and activated by three maturation stimuli, Poly I: C, LPS and the mixture of proinflammatory cytokines in order to identify the optimal combination of culture media and activation stimulus for the clinical use. Method: We tested DCs generation using two GMP-certified culture media, CellGro and RPMI+5% human AB serum and evaluated DCs morphology, viability and capapability to mature. We tested three maturation stimuli, PolyI:C, LPS and the mixture of proinflammatory cytokines consisting of IL-1, IL-6, TNF and prostaglandin E2. We evaluated the capacity of activated DCs to induce antigen-specific T cells and regulatory T lymphocytes. Results: Cell culture in CellGro resulted in a higher yield of immature DCs resulting from increased number of adherent monocytes. DCs that were genera
Czech name
—
Czech description
—
Classification
Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
EC - Immunology
OECD FORD branch
—
Result continuities
Project
<a href="/en/project/NT11559" target="_blank" >NT11559: Dendritic cell based cancer immunotherapy of prostate cancer Phase I/II clinical trial</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2011
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Journal of Translational Medicine
ISSN
1479-5876
e-ISSN
—
Volume of the periodical
9
Issue of the periodical within the volume
223
Country of publishing house
GB - UNITED KINGDOM
Number of pages
10
Pages from-to
1-10
UT code for WoS article
000299108200001
EID of the result in the Scopus database
—